FDA authorizes sample pooling for SalivaDirect PCR COVID-19 test

A new study led by an Iowa State University scientist details the structure of a critical enzyme that enables the coronavirus to resist antiviral medications. Scientists could use the study to find ways to inhibit the enzyme, possibly leading to more effective treatments.

Asthmatics who have their illness well under control have less severe COVID-19 outcomes than those with uncontrolled asthma, according to a large study conducted by USC and Kaiser Permanente Southern California.

A team of UF researchers has identified dozens of novel therapeutic targets for the development of antiviral therapies against COVID-19 and other coronaviruses that infect people.

Researchers at University at Buffalo, Johns Hopkins, and UC Davis have leveraged the power of digital pathology and computational modeling to develop a new approach to detecting and quantifying podocytes, a kidney cell key to understanding renal disease

Scientists have known for decades that a certain class of enzymes are an important player in cell biology because they frequently mutate and become major drivers of cancer. Biopharma companies are trying to develop drugs that target and inactivate these enzymes, known as phosphoinositide 3-kinase, or PI3K for short, because of their role in causing cancers in humans. But to do that, scientists need a detailed blueprint of the enzyme architecture, and UO biochemistry professor Scott Hansen is part of a group uncovering that diagram.